About   Help   FAQ
Phenotypes Associated with This Genotype
Genotype
MGI:4844195
cn2
Allelic
Composition
Cdk2tm1Sgo/Cdk2tm1Sgo
Krastm1Bbd/Kras+
Polr2atm1(cre/ERT2)Bbd/Polr2atm1(cre/ERT2)Bbd
Genetic
Background
involves: 129S1/Sv * 129X1/SvJ
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cdk2tm1Sgo mutation (1 available); any Cdk2 mutation (18 available)
Krastm1Bbd mutation (2 available); any Kras mutation (90 available)
Polr2atm1(cre/ERT2)Bbd mutation (3 available); any Polr2a mutation (92 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging
• mice treated tamoxifen at weaning exhibit an increase in lifespan of 8 weeks (42 weeks) compared with similarly treated Krastm1Bbd/Kras+ Polr2atm1(cre/ERT2)Bbd/Polr2atm1(cre/ERT2)Bbd littermates (34 weeks)

neoplasm
• tamoxifen-treated mice exhibit reduced tumor burden compared with similarly treated Krastm1Bbd/Kras+ Polr2atm1(cre/ERT2)Bbd/Polr2atm1(cre/ERT2)Bbd mice


Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources
Funding Information
Warranty Disclaimer, Privacy Notice, Licensing, & Copyright
Send questions and comments to User Support.
last database update
12/10/2024
MGI 6.24
The Jackson Laboratory